77 results on '"Stoebner PE"'
Search Results
2. Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.
- Author
-
Connell E, Gerard É, Oules B, Brunet-Possenti F, Lamoureux A, Bonnefille H, Mary-Prey S, Carrasquilla A, Mouret S, Kramkimel N, Lesage C, Stoebner PE, Bartoli A, Monestier S, Correard F, Gros A, Jeanson A, Ouafik L, Gaudy-Marqueste C, Tomasini P, Charles J, Amini-Adle M, and Malissen N
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Aged, 80 and over, Retrospective Studies, Young Adult, Skin Neoplasms drug therapy, Skin Neoplasms pathology, Skin Neoplasms genetics, Proto-Oncogene Proteins B-raf genetics, Neoplasm Metastasis, Membrane Proteins, GTP Phosphohydrolases, Melanoma drug therapy, Melanoma pathology, Melanoma genetics, Molecular Targeted Therapy methods
- Abstract
Background: Only a fraction of patients with metastatic melanoma derive durable benefit from approved treatments. The clinical impact of personalized medicine strategies for melanoma, apart from BRAF, NRAS, or CKIT targeting, has rarely been reported., Materials and Methods: By means of the Group of Cutaneous Oncology of the French Society of Dermatology, we retrospectively included all patients with advanced melanoma aged 18 years and older for whom molecular testing identified one or more actionable molecular alterations and who accordingly received molecularly matched therapy. We excluded patients with only BRAF, NRAS, or CKIT alterations and patients who received molecularly matched therapy for less than 15 days., Results: We included 26 patients with a median follow-up of 8 months (1-54), a median age of 63 years (24-89), and a sex ratio of 2.7. These patients had been heavily pretreated, and 64% had elevated LDH levels. The disease control rate was 38%, with 4 cases of partial response (overall response rate: 15%) and 6 of stable disease for at least 6 months. The median duration of treatment was 3.1 months (0.9-13.5). Among patients with disease control, the median duration of control was 6.6 months (2.6-13.5) and 3 cases were ongoing at the end of the study. Patients with controlled disease had GNA11, MAP2K1, FYCO1-RAF1, HRAS, ATM, CCND1, MDM2/CDK4, and CDKN2A/NRAS alterations., Conclusions: High-throughput sequencing followed by matched targeted therapy is a promising approach for patients with advanced melanoma refractory to approved treatments., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
3. Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm.
- Author
-
Poizeau F, Leducq S, Fardet L, Beylot-Barry M, Chaby G, Chastagner M, Corgibet F, Gouillon L, Jouan N, Jullien D, Acher A, Amatore F, Amici JM, Aubert H, Aubin F, Beneton N, Bouilly D, Bursztejn AC, Buzenet C, Chamaillard-Pujol M, Charles J, Cottencin-Charriere AC, Duval Modeste B, Fauconneau A, Fougerousse AC, Girard C, Goujon C, Khemis A, Le Ru Y, Lepelley-Dupont C, Mahé E, Marcellin X, Nicolas C, Pallure V, Parier J, Quiles N, Stoebner PE, Tauber M, Vermersch A, Viguier M, Villani AP, Chosidow O, and Guillot B
- Abstract
Background: New highly effective drugs for moderate-to-severe cutaneous psoriasis are regularly marketed, and the hierarchy of treatments thus requires frequent review., Objectives: A Delphi method was used to enable a structured expert consensus on the use of systemic treatments and phototherapy among adults with moderate-to-severe psoriasis., Methods: The Delphi method consists in achieving a convergence of opinions among a panel of experts using several rounds of questionnaires with controlled feedback between rounds. A two-part Delphi questionnaire was administered online to French psoriasis experts. In the first part, 180 items related to the prescription of systemic treatments and phototherapy for adult patients with moderate-to-severe psoriasis were grouped into 21 sections covering different lines of treatment and different forms of cutaneous psoriasis. The experts voted on each proposal using an ordinal 7-point Likert scale. The second part comprised 11 open-ended questions about special indications for each therapeutic class. These were converted into 101 questions for subsequent rounds. Consensus was deemed to have been reached if more than 80% of the experts agreed with a given proposal., Results: Three rounds of questionnaires were sequentially sent to 35 participants between November 2021 and March 2022. Thirty-three (94%) completed all three rounds. For plaque psoriasis, only methotrexate was recommended by the experts as first-line systemic treatment (89% of votes). Cyclosporin was advocated in pustular and erythrodermic psoriasis, and acitretin was suggested for hyperkeratotic and palmoplantar psoriasis. In the event of failure of or intolerance to non-biological systemic treatments, guselkumab, risankizumab, ixekizumab or secukinumab were recommended by more than 80% of the experts. Tumor Necrosis Factor (TNF) inhibitors remain useful for patients with cardiovascular risk factors. Special indications were provided for each therapeutic class (methotrexate/narrowband ultraviolet B phototherapy, psoralen/ultraviolet A phototherapy, cyclosporin, acitretin, apremilast, TNF inhibitors, interleukin (IL)-12/23 inhibitors, IL-17(R)A inhibitors, and IL-23 inhibitors)., Conclusions: This expert consensus statement indicate that newly available IL-17 and IL-23 inhibitors may be favored over TNF and IL-12/23 inhibitors as first-line biologics. The Centre of Evidence of the French Society of Dermatology has drawn up a decision-making algorithm to guide clinicians in the therapeutic management of moderate-to-severe psoriasis., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Two cases of multiple onychomatricomas affecting the fingers on both hands.
- Author
-
Samaran Q, Moulonguet I, Bonnefille H, Stoebner PE, Zaraa I, Goettmann S, and Ovtchinnikoff B
- Published
- 2024
- Full Text
- View/download PDF
5. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
- Author
-
Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, and Boespflug A
- Subjects
- Humans, Nivolumab therapeutic use, Ipilimumab therapeutic use, Proto-Oncogene Proteins B-raf genetics, France, Antineoplastic Combined Chemotherapy Protocols, Melanoma drug therapy, Melanoma genetics, Skin Neoplasms drug therapy, Skin Neoplasms genetics
- Published
- 2024
- Full Text
- View/download PDF
6. Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey.
- Author
-
Samaran Q, Samaran R, Ferreira E, Haddad N, Fottorino A, Maillard H, Dreno B, Meyer N, Azria D, Maubec E, Gaudy-Marqueste C, Molinari N, Stoebner PE, and Dereure O
- Subjects
- Humans, Aged, Retrospective Studies, Immune Checkpoint Inhibitors adverse effects, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology, Skin Neoplasms drug therapy, Skin Neoplasms pathology, Antineoplastic Agents, Immunological adverse effects
- Abstract
Background: Anti-PD1 agents are currently recommended as first-line treatment in advanced cutaneous squamous cell carcinoma (acSCC) by updated European guidelines. Although acSCC frequently affects elderly patients with multiple comorbidities, this subset of patients is often excluded of registration clinical trials., Purpose: To assess anti-PD-1 efficacy and safety in elderly acSCC patients in real-life conditions and describe this specific population with oncogeriatric evaluation tools., Methods: A multicenter retrospective study including acSCC patients at least 70 years old treated with PD-1 inhibitors was conducted in French referral centers. The primary endpoint was the overall response rate (ORR). Secondary endpoints included safety data, time to response (TTR), duration of response (DOR), overall survival (OS), and progression-free survival (PFS)., Results: 63 patients were included. ORR was 57.1% (95% CI 44.0-69.5), median TTR and DOR were 3 and 5.5 months respectively. Median OS was not reached (95% CI 12.5 months-not reached) at data cut-off after a median follow-up of 8 months while median PFS was 8 months. (95% CI 5 months-not reached). Grade 3-5 adverse effects occurred in 47.6% of patients. 41.3% of patients experienced degradation of ECOG performance status during anti-PD-1 treatment. Nutritional state worsened in 27% of patients and 57.1% lost weight during treatment., Conclusion: In this particular subset of acSCC patients PD-1 inhibitors obtain results similar to those obtained in younger populations included in pivotal clinical trials, with acceptable safety. A specific oncogeriatric evaluation at treatment initiation and during follow-up appears important in this setting most notably to help manage toxicity., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
7. Using of a Foam Earplug: A Nose Surgery Pearl.
- Author
-
Samaran Q, Stoebner PE, and Ovtchinnikoff B
- Subjects
- Humans, Ear Protective Devices, Nose surgery
- Published
- 2023
- Full Text
- View/download PDF
8. A deep-learning algorithm to localize basal cell carcinoma foci on Mohs surgery frozen sections.
- Author
-
Bonnefille H, Abbas M, Roger P, Habib F, Masset F, Chaumont M, Subsol G, and Stoebner PE
- Subjects
- Humans, Mohs Surgery, Frozen Sections, Deep Learning, Carcinoma, Basal Cell surgery, Carcinoma, Basal Cell pathology, Skin Neoplasms surgery, Skin Neoplasms pathology
- Published
- 2023
- Full Text
- View/download PDF
9. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.
- Author
-
Rousset P, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Brunet-Possenti F, De Quatrebarbes J, Grob JJ, Saiag P, Maubec E, Stoebner PE, Granel-Brocard F, Arnault JP, Allayous C, Oriano B, Lebbe C, and Montaudié H
- Subjects
- Humans, Immunotherapy, Progression-Free Survival, Skin pathology, Neoplasms, Unknown Primary pathology, Melanoma pathology, Skin Neoplasms pathology
- Abstract
Background: Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied., Objective: To investigate the efficacy and safety of systemic treatments in patients with advanced MUP compared to patients with stage-matched melanoma of known cutaneous primary (cMKP)., Methods: Based on the nationwide MelBase prospective database, this study included advanced melanoma patients treated from March 2013 to June 2021 with first-line immunotherapies, targeted therapies, or chemotherapy. Co-primary outcomes were progression-free survival and overall survival. Secondary outcome was treatment-related toxicities. Multivariate and propensity score analyses were performed., Results: Of 1882 patients, 265 (14.1%) had advanced MUP. Patients with advanced MUP displayed more often unfavorable initial prognostic factors than those with cMKP. Progression-free and overall survival did not differ significantly between the groups (P = .73 and P = .93, respectively), as well as treatment-related toxicity rate and severity, regardless of treatment type., Limitations: No record of standard diagnostic criteria of MUP used in the participating centers., Conclusions: Although patients with MUP had less favorable baseline prognostic factors, they benefited from the novel therapies as much as those with cMKP. They should be managed according to similar strategies., Competing Interests: Conflicts of interest Dr Dalle received research grants by BMS and MSD, travel costs covered by BMS, spouse working for Sanofi; Dr Dereure reported a Consulting or Advisory Role with Bristol-Myers Squibb, Genevrier, Kiowa Kirin, Leo Pharma, MSD, Novartis, Pierre Fabre, and Recordati, and reports travel, accommodations, and expenses from Bristol-Myers Squibb, Novartis, Pierre Fabre, and Recordati; Dr Saiag has received outside of this study personal fees from Bristol-Myers Squibb, MSD, Merck-Serono, Pfizer, Roche-Genentech, Pierre Fabre, and Novartis; Dr Arnault consulting for NOVARTIS, Dr Lebbé reported honoraria from Amgen, Bristol-Myers Squibb, Incyte, MSD, Novartis, Pfizer, Pierre Fabre, and Roche, reports a Consulting or Advisory Role with Amgen, Bristol-Myers Squibb, Merck Serono, MSD, Novartis, Roche, and Sanofi, is on the Speakers' Bureau for Amgen, Bristol-Myers Squibb, MSD, Novartis, and Roche, received Research Funding from Bristol-Myers Squibb, and Roche, reports travel, accommodations, and expenses from Bristol-Myers Squibb and MSD, and reports other relationship with Avantis Medical Systems; and Dr Montaudié reported a Consulting or Advisory Role with Bristol-Myers Squibb, MSD, Novartis, and Pierre Fabre, received Research Funding from Leo Pharma and Novartis, and reports travel, accommodations, and expenses from Bristol-Myers Squibb, Novartis, and Pierre Fabre., (Copyright © 2022 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Clinicopathologic and molecular analyses of cutaneous leiomyosarcoma: A retrospective, multicenter study of 79 cases.
- Author
-
Planet C, Dalle S, Dereure O, Stoebner PE, Picot MC, Soler M, Meunier L, Cardot-Leccia N, Kubiniek V, Di Mauro I, Delhorbe M, Lacour JP, Passeron T, Pedeutour F, Montaudié H, and Dadone-Montaudié B
- Subjects
- Humans, Female, Retrospective Studies, Leiomyosarcoma genetics, Leiomyosarcoma pathology, Uterine Neoplasms, Skin Neoplasms genetics, Skin Neoplasms pathology
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2023
- Full Text
- View/download PDF
11. Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France.
- Author
-
Kandel M, Bardet A, Dalle S, Allayous C, Mortier L, Guillot B, Dutriaux C, Leccia MT, Dalac S, Montaudie H, Saiag P, Legoupil D, Brunet-Possenti F, Arnault JP, Quatrebarbes J, Beylot-Barry M, Maubec E, Lesimple T, Aubin F, Grob JJ, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, and Borget I
- Subjects
- Humans, Cost-Benefit Analysis, Prospective Studies, Proto-Oncogene Proteins B-raf genetics, France, Cost-Effectiveness Analysis, Melanoma drug therapy, Melanoma genetics
- Abstract
Nine drugs have been marketed for 10 years for the treatment of advanced melanoma (AM). With half of patients reaching a second line, the optimal sequence of treatments remains unclear. To inform policy-makers about their efficiency, we performed a cost-effectiveness analysis of sequential strategies in clinical practice in France, for BRAF-mutated and wild-type patients. A multistate model was developed to describe treatment sequences, associated costs, and health outcomes over 10 years. Sequences, clinical outcomes, utility scores, and economic data were extracted from the prospective Melbase cohort, collecting individual data in 1518 patients since 2013, from their AM diagnosis until their death. To adjust the differences in patients' characteristics among sequences, weighting by inverse probability was used. In the BRAF-mutated population, the MONO-targeted therapies (TT)-anti-PD1 sequence was the less expensive, whereas the anti-PD1-BI-TT sequence had an incremental cost-effectiveness ratio (ICER) of 180,441 EUR/QALY. Regarding the BRAF wild-type population, the three sequences constituted the cost-effective frontier, with ICERs ranging from 116 to 806,000 EUR/QALY. For BRAF-mutated patients, the sequence anti-PD1-BI-TT appeared to be the most efficient one in BRAF-mutated AM patients until 2018. Regarding the BRAF wild-type population until 2018, the sequence starting with IPI+NIVO appeared inefficient compared to anti-PD1, considering the extra cost for the QALY gained.
- Published
- 2022
- Full Text
- View/download PDF
12. Lichen planus in psoriatic patients treated with interleukin 17 inhibitors: two additional cases and a literature review
- Author
-
Toumi A, Molva M, Bergeret B, Marque M, and Stoebner PE
- Subjects
- Humans, Interleukin-17, Lichen Planus
- Published
- 2022
- Full Text
- View/download PDF
13. Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
- Author
-
Girod M, Dalle S, Mortier L, Dalac S, Leccia MT, Dutriaux C, Montaudié H, de Quatrebarbes J, Lesimple T, Brunet-Possenti F, Saiag P, Maubec E, Legoupil D, Stoebner PE, Arnault JP, Lefevre W, Lebbe C, and Dereure O
- Subjects
- Humans, Proto-Oncogene Proteins B-raf genetics, Prospective Studies, Protein Kinase Inhibitors therapeutic use, Mutation, Mitogen-Activated Protein Kinase Kinases genetics, Melanoma drug therapy, Neoplasms, Second Primary
- Abstract
Purpose: Mitogen-activating protein kinase inhibitors (MAPKis) are largely used in V600E/K BRAF-mutated metastatic melanomas, but data regarding effectiveness of targeted therapy in patients with rare BRAF mutations and molecular description of these infrequent mutations are scarce., Patients and Methods: A multicenter study was conducted on patients with metastatic melanoma harboring a well-identified mutation of BRAF and enrolled from March 2013 to June 2021 in the French nationwide prospective cohort MelBase. The molecular BRAF mutation pattern, response to MAPKis when applicable, and survival data were analyzed., Results: Of 856 selected patients, 51 (6%) harbored a non-V600E/K BRAF mutation involving codons V600 (24 of 51, 47%; V600G 27.4%, V600R 15.6%), K601 (6 of 51, 11.7%), and L597 (4 of 51, 7.8%). An objective response to MAPKis either BRAF inhibitor (BRAFi) alone or combined with MEK inhibitor was achieved in 56% (353 of 631) of V600E/K, 58% (11 of 19) of non-E/K V600, and 22% (2 of 9) of non-V600 BRAF-mutated patients, with a median progression-free survival of 7.7, 7.8, and 2.8 months, respectively. Overall, objective response rate was higher with BRAFi + MEK inhibitor combination than with BRAFi in monotherapy for each subset., Conclusion: Rare BRAF mutations are not anecdotal in the metastatic melanoma population. Although data interpretation must remain careful owing to the limited size of some subsets of patients, non-E/K V600 BRAF mutations seem to confer a high sensitivity to targeted therapy, whereas MAPKis seem less effective in patients with non-V600 BRAF mutations. However, this strategy may be used as an alternative option in the case of immunotherapy failure in the latter population.
- Published
- 2022
- Full Text
- View/download PDF
14. Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
- Author
-
Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, Montaudié H, Arnault JP, De Quatrebarbes J, Saiag P, Brunet-Possenti F, Lesimple T, Maubec E, Aubin F, Granel-Brocard F, Grob JJ, Stoebner PE, Allayous C, Oriano B, Dutriaux C, Mortier L, and Lebbe C
- Subjects
- Case-Control Studies, Humans, Immune Checkpoint Inhibitors adverse effects, Prospective Studies, Retrospective Studies, Antineoplastic Agents, Immunological adverse effects, Autoimmune Diseases chemically induced, Autoimmune Diseases drug therapy, Immune System Diseases, Melanoma drug therapy
- Abstract
Objective: To quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma., Methods: Case-control study performed on a French multicentric prospective cohort of patients with melanoma, matched for irAE risk factors and oncological staging. Risk of irAE was assessed by logistic regression., Results: 110 patients with pAID were included and matched with 330 controls, from March 2013 to October 2020. Over a median follow-up period of 7.2 months for cases and 6.9 months for controls, the ORs of developing all-grade and grade ≥3 irAEs among cases compared with controls were 1.91 (95% CI (1.56 to 2.27)) and 1.44 (95% CI (1.08 to 1.82)), respectively. Patients with pAID had an increased risk of multiple irAEs (OR 1.46, 95% CI (1.15 to 2.67)) and a shorter time to irAE onset. In contrast, there were no difference in irAE-related mortality nor in the rate of treatment discontinuation, and a landmark analysis revealed a better survival at 24 months among cases (p=0.02). Thirty per cent of cases experienced a pAID flare during follow-up, and baseline immunosuppression did not prevent irAE occurrence. Last, we report associations between the pAID clinical subsets and organ-specific irAEs., Conclusion: In our study, patients with pAID were at greater risk of all-grade, severe and multiple irAEs, yet had a better 24-month survival than controls. Thus, patients with pAID should be eligible for ICI therapy but benefit from a close monitoring for irAE occurrence, especially during the first months of therapy., Competing Interests: Competing interests: DL: fees from Novartis, BMS et MSD. PS: consulting fees from Roche, Novartis, BMS, Pierre FABRE, MSD. FB-P: consulting fees from BMS and Sanofi. TL: consulting fees from MSD, BMS, Pierre Fabre, Novartis. J-JG : consulting fees from MSD, Roche, Novartis, Amgen, Pierre-Fabre, Sanofi, Philogen, Merck, Pfizer. CA: grants from Amgen, BMS, Roche. LM: grants from BMS, Novartis, Roche, MSD, GSK, Pierre Fabre and consulting fees from BMS, Novartis, Roche, MSD, GSK, Pierre Fabre. CL: grants from BMS, MSD, Novartis, Sanofi, Pierre Fabre; consulting fees from BMS, MSD, Novartis, Amgen, Roche, Merck, Serono, Sanofi, Pierre Fabre and teaching fees from Roche, BMS, Novartis, Amgen, MSD., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
15. Diagnostic Accuracy of Digital Staining ex vivo Confocal Microscopy for Diagnosing and Subtyping Basal Cell Carcinoma in Fresh Pretherapeutic Punch Biopsies: A Monocentric Prospective Study.
- Author
-
Bergeret B, Masset F, Bekoy YD, Roger P, Habib F, Ovtchinnikoff B, Meunier L, and Stoebner PE
- Abstract
Background: Ex vivo confocal microscopy using fusion mode and digital staining (EVCM) scans unfixed fresh tissue and produces rapidly digitally stained images of very similar quality to classical pathology. We investigated whether EVCM could represent an alternative to the standard histological examination of the pretherapeutic basal cell carcinoma (BCC) punch biopsies., Objectives: The objective of the study was to assess diagnostic accuracy of EVCM versus traditional histopathological examination for diagnosing and subtyping clinically suspicious lesions of BCC in 3-mm fresh and nonfixed punch biopsies., Methods: In this prospective monocentric observational study, patients with clinically suspected BCC were consecutively enrolled. Punch biopsies were imaged using EVCM and subsequently processed for standard histologic examination (gold standard). EVCM images were examined by a dermatopathologist blinded to clinical aspect of the lesion and histopathological results. Concordance between the EVCM and histology analysis was calculated with Cohen's kappa (κ) statistic., Results: Sixty-six patients were recruited, and 106 biopsies were analyzed. EVCM correctly diagnosed 70/73 BCCs and 31/33 non-BCC lesions, corresponding to a sensitivity of 96% and a specificity of 94% (positive predictive value = 97%, negative predictive value = 91%). The EVCM assessment led to over-staging and under-staging of BCC subtypes in 5% and 11% of cases, respectively. It led to over-staging and under-staging of BCC depths in 5% and 15%, respectively. The kappa coefficient for concordance was 0.78 (95% confidence interval [CI]: 0.69-0.88) when considering BCC subtypes and 0.81 (95% CI: 0.72-0.90) when considering BCC depths., Conclusions: These results render EVCM as a promising option for "real-time" pretreatment evaluation of clinically suspected BCC lesions. Further larger randomized studies are needed to assess the efficiency of EVCM versus standard care in patients with clinically suspected BCC., (© 2022 S. Karger AG, Basel.)
- Published
- 2022
- Full Text
- View/download PDF
16. Extracellular 20S proteasome secreted via microvesicles can degrade poorly folded proteins and inhibit Galectin-3 agglutination activity.
- Author
-
Bonhoure A, Henry L, Bich C, Blanc L, Bergeret B, Bousquet MP, Coux O, Stoebner PE, and Vidal M
- Subjects
- Agglutination, Cytoplasm metabolism, Humans, Proteolysis, Galectin 3 metabolism, Proteasome Endopeptidase Complex metabolism
- Abstract
Proteasomes are major non-lysosomal proteolytic complexes localized in the cytoplasm and in the nucleus of eukaryotic cells. Strikingly, high levels of extracellular proteasome have also been evidenced in the plasma (p-proteasome) of patients with specific diseases. Here, we examined the process by which proteasomes are secreted, as well as their structural and functional features once in the extracellular space. We demonstrate that assembled 20S core particles are secreted by cells within microvesicles budding from the plasma membrane. Part of the extracellular proteasome pool is also free of membranes in the supernatant of cultured cells, and likely originates from microvesicles leakage. We further demonstrate that this free proteasome released by cells (cc-proteasome for cell culture proteasome) possesses latent proteolytic activity and can degrade various extracellular proteins. Both standard (no immune-subunits) and intermediate (containing some immune-subunits) forms of 20S are observed. Moreover, we show that galectin-3, which displays a highly disordered N-terminal region, is efficiently cleaved by purified cc-proteasome, without SDS activation, likely after its binding to PSMA3 (α7) subunit through its intrinsically disordered region. As a consequence, galectin-3 is unable to induce red blood cells agglutination when preincubated with cc-proteasome. These results highlight potential novel physio- and pathologic functions for the extracellular proteasome., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
17. Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells.
- Author
-
Bonhoure A, Henry L, Morille M, Aissaoui N, Bellot G, Stoebner PE, and Vidal M
- Subjects
- Animals, Humans, Melanoma pathology, Mice, Skin Neoplasms pathology, Exosomes genetics, Melanoma genetics, Membrane Glycoproteins metabolism, Skin Neoplasms genetics
- Abstract
Cutaneous melanoma is the most lethal type of skin cancer. Early detection is crucial to improve the outcome of melanoma patients. The identification of noninvasive prognostic biomarkers for the follow-up of melanoma patients is still in demand for clinical use. We show here that exosomal melanotransferrin fulfills the biomarker characteristics required to meet this demand. Melanotransferrin is typically overexpressed in melanoma cells compared to other cell types - including cancer cells - and is efficiently sorted and secreted with nanovesicles, or so-called exosomes, due to its membrane-anchoring by a glycosylphosphatidylinositol. Melanotransferrin is exposed on the surface of exosomes and is accessible for antibody recognition. An ELISA was set up to quantify melanotransferrin after immobilization of nanovesicles through the exosomal constituent tetraspanins CD63. Melanotransferrin was detected using a low number of exosomes purified from melanoma cell line cultures, and melanotransferrin detection was abolished by phosphatidylinositol-specific phospholipase C treatment. This exosomal melanotransferrin ELISA was able to discriminate an equal number of assayed exosomes purified from two different melanoma cell lines (A-375 vs. SK-MEL-28). Moreover, plasma samples from patients with melanoma and noncancer disease were assayed using this ELISA and elevated levels of exosomal melanotransferrin were seen in the plasma of patients with melanoma. We propose that exosomal melanotransferrin should be assessed as a potential melanoma biomarker., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
18. Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.
- Author
-
Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, Meyer N, Duval-Modeste AB, Cesaire L, Neidhardt ÈM, Archier É, Dréno B, Lesage C, Berthin C, Kramkimel N, Grange F, de Quatrebarbes J, Stoebner PE, Poulalhon N, Arnault JP, Abed S, Bonniaud B, Darras S, Heidelberger V, Devaux S, Moncourier M, Misery L, Mansard S, Etienne M, Brunet-Possenti F, Jacobzone C, Lesbazeilles R, Skowron F, Sanchez J, Catala S, Samimi M, Tazi Y, Spaeth D, Gaudy-Marqueste C, Collard O, Triller R, Pracht M, Dumas M, Peuvrel L, Combe P, Lauche O, Guillet P, Reguerre Y, Kupfer-Bessaguet I, Solub D, Schoeffler A, Bedane C, Quéreux G, Dalac S, Mortier L, and Maubec È
- Abstract
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%; partial, 29%). With median follow-up at 12.6 months, median PFS was 7.9 months, and median OS and DOR were not reached. One-year OS was 73% versus 36%, respectively, for patients with PS < 2 versus ≥ 2. Multivariate analysis retained PS ≥ 2 as being associated during the first 6 months with PFS and OS. Head-and-neck location was associated with longer PFS. Immune status had no impact. Severe treatment-related adverse events occurred in 9% of the patients, including one death from toxic epidermal necrolysis. Cemiplimab real-life safety and efficacy support its use for la/mCSCCs. Patients with PS ≥ 2 benefited less from cemiplimab, but it might represent an option for immunocompromised patients.
- Published
- 2021
- Full Text
- View/download PDF
19. Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma.
- Author
-
Becquart O, Oriano B, Dalle S, Mortier L, Leccia MT, Dutriaux C, Dalac S, Montaudié H, De Quatrebarbes J, Brunet-Possenti F, Saiag P, Lesimple T, Beylot-Barry M, Aubin F, Stoebner PE, Arnault JP, Dreno B, Porcher R, Lebbe C, and Guillot B
- Abstract
Purpose: Melanoma's incidence is increasing, and elderly people could be significantly impacted since the majority occurs in people over 65 years of age. Combined BRAF and MEK targeted therapies (TT) are current standard regimen for BRAF mutated metastatic melanoma (MM). Except for subgroups of pivotal trials, little data are available for TT in this population., Materials and Methods: Outcomes were explored in real life patients from MelBase, a French multicentric biobank dedicated to the prospective follow-up of unresectable stage III or IV melanoma. Patients treated by BRAF TT and/or MEK TT combined or not, were included from 2013 to 2017 in 2 groups: group 1 ≤ 65-year-old (yo), group 2 > 65 yo, analyzed for tolerance and efficacy., Results: 353 patients were included: 231 in group 1, 122 in group 2. Median follow-up was 12 months (M). Median time of treatment was 6.9 M. A total of 80% had at least one Adverse Effect (AE). Most frequent AE (all grades) were mainly skin and subcutaneous, general, and gastrointestinal disorders. A total of 31% of AE were grade 3-4: 28% in group 1 and 39% in group 2 ( p = 0.05). No differences were observed in all AE grades proportion, dose modifications, interruptions, and discontinuations. For each group, median overall survival was 20.3 M (CI 95%: 15.5-27.9) and 16.3 M (CI: 14.5-26.9), respectively ( p = 0.8). Median progression free survival was 7.8 M (6.4-9.9) and 7.7 M (CI: 5.8-11.3) ( p = 0.4). Objective response rate was 59% and 50% ( p = 0.6)., Conclusion: This study on a large multicentric cohort is the first to assess that TT is well tolerated in elderly BRAF-mutated patients such as in patients younger than 65. Efficacy was similar between groups with outcomes reaching those from pivotal studies. There is thus no argument against using TT in elderly people, although an onco-geriatric opinion is welcome for the most vulnerable.
- Published
- 2021
- Full Text
- View/download PDF
20. Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data ☆ .
- Author
-
Di Filippo Y, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Saiag P, Brunet-Possenti F, Arnnault JP, Maubec E, Granel-Brocard F, De Quatrebarbes J, Aubin F, Lesimple T, Beylot-Barry M, Stoebner PE, Dupuy A, Stephan A, Grob JJ, Lefevre W, Oriano B, Allayous C, Lebbé C, and Montaudié H
- Subjects
- Adult, Aged, Body Mass Index, Humans, Male, Progression-Free Survival, Prospective Studies, Retrospective Studies, Melanoma drug therapy, Melanoma epidemiology
- Abstract
Background: The 'obesity paradox' suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those receiving targeted and immune checkpoint inhibitor therapy. Higher BMI is also associated with higher incidences of treatment-related adverse events (TRAEs). This study assesses whether BMI is associated with survival outcomes and adverse events in metastatic melanoma patients with systemic therapy., Patients and Methods: This multicentric retrospective study, conducted from 1 March 2013 to 29 April 2019, enrolled adults with unresectable stage III or IV melanoma from the French multicentric prospective cohort-MelBase (NCT02828202). Patients with first-line chemotherapy and targeted and immune therapy were included. Underweight people and those with metastatic mucosal or ocular melanoma were excluded. BMI was categorized using the World Health Organization criteria. Co-primary outcomes included the association between BMI and progression-free survival and overall survival, stratified by treatment type, sex, and age. Secondary endpoints were the association of BMI with overall response and TRAEs. Multivariate analyses were carried out., Results: A total of 1214 patients were analyzed. Their median age was 66.0 years (range, 53-75). Male predominance was observed [n = 738 (61%)]. Most patients received immune checkpoint inhibitor therapy (63%), followed by targeted therapy (32%), and had stage M1c disease (60.5%). Obese patients represented 22% of the cohort. The median follow-up duration was 13.5 months (range, 6.0-27.5). In the pooled analysis, no positive or negative association between BMI and progression-free survival (P = 0.88)/overall survival (P = 0.25) was observed, regardless of treatment type, sex, and age. These results were nonsignificant in the univariate and multivariate analyses. The objective response rate, according to BMI category, did not differ significantly regardless of age. TRAEs were not associated with BMI., Conclusion: The observed lack of an association between BMI and survival demonstrates that BMI is not a valuable marker of systemic treatment-related outcomes in metastatic melanoma. Future approaches might focus on the whole-body distribution., Competing Interests: Disclosure StD reports institutional research funding from Roche; institutional research funding and nonfinancial support from Bristol-Myers Squibb (BMS); and an immediate family member who is employed by Sanofi and owns stock or other ownership interest in the company. LM reports personal fees and nonfinancial support from Roche, Novartis, BMS, and Merck Sharp & Dohme (MSD) outside the submitted work. OD reports personal fees and nonfinancial support from BMS, MSD, Pierre Fabre, Novartis, Leo Pharma, Genevrier, Kyowa Kirin, Recordati Rare Diseases outside the submitted work. SoD received research funding and travel costs covered by BMS and MSD. Travel costs covered by Pierre Fabre. CD reports personal fees from Roche, BMS, Novartis, MSD, and Pierre Fabre Laboratories outside the submitted work. PS reports research funding and personal fees from Roche; grants, personal fees, and nonfinancial support from BMS, MSD, Novartis, and Pierre Fabre Laboratories; and personal fees from Array, Sanofi, and Merck, all outside the submitted work. J-PA reports personal fees from BMS, grants from BMS, Novartis, and MSD, during the conduct of the study. EM reports grants, personal fees, and nonfinancial support from MSD; personal fees from Sanofi and Novartis; personal fees and nonfinancial support from BMS; and nonfinancial support from Pierre Fabre Laboratories, all outside the submitted work. JDQ reports nonfinancial support from BMS, MSD, and Janssen outside the submitted work. FA reports personal fees and nonfinancial support from Novartis, MSD, and Roche outside the submitted work. TL reports research funding and personal fees from Roche and personal fees from BMS, MSD, Novartis, Pierre Fabre Laboratories, and Incyte, all outside the submitted work. P-ES reports travel accomodations -meetings by BMS, Novartis, MSD, and Sanofi. J-JG reports personal fees and nonfinancial support from BMS, Roche, MSD, Novartis, Merck, Amgen, Pierre Fabre Laboratories, Sanofi, and Pfizer and nonfinancial support from Amgen, all outside the submitted work. CA reports travel accommodations-meetings by Roche, BMS, and Amgen. CL reports grants and personal fees from BMS, personal fees from MSD, personal fees from Novartis, personal fees from Amgen, grants and personal fees from Roche, personal fees from Avantis Medical Systems, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Incyte, personal fees from Merck Serono, personal fees from Sanofi, outside the submitted work. HM reports institutional research funding from LeoPharma; institutional research funding, personal fees, and nonfinancial support from BMS; personal fees from Pierre Fabre Laboratories and MSD; and nonfinancial support from Novartis, all outside the submitted work. All other authors have declared no conflicts of interest., (Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
21. Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity.
- Author
-
Henri P, Prevel C, Pellerano M, Lacotte J, Stoebner PE, Morris MC, and Meunier L
- Subjects
- Cyclin-Dependent Kinase Inhibitor p16 genetics, Cyclin-Dependent Kinase Inhibitor p27 genetics, Epidermal Cells metabolism, Epidermis metabolism, Epidermis pathology, Humans, Proto-Oncogene Proteins, Up-Regulation, Cyclin-Dependent Kinase 2 genetics, Cyclin-Dependent Kinase 4 genetics, Psoriasis genetics
- Abstract
Background: The cyclin-dependent kinases (CDKs) CDK2 and CDK4 are involved in regulation of cell-cycle progression, and psoriasis is characterized by hyperproliferation of basal epidermal cells. CDK inhibitory proteins (CKIs) such as p16
INK 4A (p16) bind CDK4/6 kinases and prevent their interaction with D-type cyclins. CKIs such as p21Cip1 (p21) and p27Kip1 (p27) associate with CDK-cyclin complexes and prevent their activation., Objectives: To gain insight into the molecular implication of CDK2 and CDK4 kinases in psoriasis, we sought to characterize expression of these kinases and associated cyclins, as well as of CKIs, and addressed the status of CDK2 and CDK4 activity in human psoriatic epidermis., Methods: A cohort of 24 patients with psoriasis participated in the study. Biopsies were removed from a chronic plaque and from nonlesional skin. CDK2, CDK4, cyclin D1, cyclin E and CKI protein expression was assessed by immunoblotting, immunohistochemistry and immunofluorescence. CDK4 and CDK2 mRNA expression was determined by real-time polymerase chain reaction. Specific kinase activities of CDK2 and CDK4 were evaluated using fluorescent peptide biosensors., Results: CDK2-cyclin E expression and activity were significantly increased in psoriatic epidermis compared with uninvolved adjacent skin. In contrast, CDK4-cyclin D1 activity was inhibited, although its expression was increased in psoriatic epidermis and its transcription slightly inhibited. p27 expression was reduced, while p16 and p21 expression was induced in psoriatic epidermis., Conclusions: Epidermal CDK2 activity is increased in psoriatic epidermis while CDK4 activity is completely inhibited. These alterations are not associated with changes in CDK transcription and instead involve post-translational control mediated by decreased expression of p27 and p16 overexpression, respectively. What's already known about this topic? Cyclin-dependent kinases (CDKs) are involved in cell-cycle progression. The levels of cyclin partners and CDK inhibitors regulate their activity. Psoriasis is a chronic T-cell-driven inflammatory skin disease characterized by hyperproliferation of basal epidermal cells. What does this study add? Thanks to fluorescent peptide biosensors, this study demonstrates that epidermal CDK2 activity is increased in psoriatic epidermis while CDK4 activity is completely inhibited. These alterations involve post-translational control mediated by decreased expression of p27, and p16 overexpression, respectively. What is the translational message? CDK2 and CDK4 are involved in regulation of cell-cycle progression, and psoriasis is characterized by hyperproliferation of basal epidermal cells. Epidermal CDK2 activity is increased in psoriatic epidermis while CDK4 activity is completely inhibited. These alterations are not associated with changes in CDK transcription and instead involve post-translational control mediated by decreased expression of p27 and p16 overexpression, respectively. Pharmacological modulation of CDK2 and CDK4 may constitute a promising therapeutic strategy., (© 2019 British Association of Dermatologists.)- Published
- 2020
- Full Text
- View/download PDF
22. Quality-of-life assessment in French patients with metastatic melanoma in real life.
- Author
-
Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, and Borget I
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cohort Studies, Disease Progression, Female, France epidemiology, Humans, Male, Melanoma immunology, Melanoma pathology, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasms, Second Primary immunology, Neoplasms, Second Primary pathology, Prospective Studies, Quality of Life, Survival Rate, Young Adult, Immunotherapy, Melanoma epidemiology, Melanoma therapy, Neoplasms, Second Primary epidemiology
- Abstract
Background: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life., Methods: QoL data were collected through MelBase, a prospective, French, multicentric cohort dedicated to the follow-up of adults with MM. QoL was assessed using the EuroQoL-5D questionnaire and the Functional Assessment of Cancer Treatment (FACT)-Melanoma questionnaire at the time of study inclusion, every 3 months, and at the time of each treatment change until death. To assess longitudinal changes from baseline to death, mixed-effect models for repeated-measures analyses were used to control for baseline covariates., Results: QoL was assessed in 1435 patients who were included in the study between 2013 and 2018. The median follow-up was 9.4 months, and 47% of patients died during follow-up. During first-line treatment, the model-based, mean utility score was 0.830 (95% CI, 0.818-0.843), the mean FACT-General score was 77.22 (95% CI, 76.23-78.22), and the mean FACT-Melanoma score was 129.46 (95% CI, 128.02-130.90). At the time of a change in treatment line, there was a decrease of -0.027 (95% CI, -0.03, -0.02) in the utility score, -1.82 (95% CI, -1.88, -1.76) in the FACT-General score, and -2.98 (95% CI, -3.05, -2.91) in the FACT-Melanoma score compared with first-line treatment., Conclusions: In the MelBase cohort, the QoL among patients with MM seems to be fairly stable over the whole disease course, although a small but significant decrease at time therapy is changed is observed., (© 2019 American Cancer Society.)
- Published
- 2020
- Full Text
- View/download PDF
23. Herpetic glossitis.
- Author
-
Schwob E, Dandurand M, and Stoebner PE
- Subjects
- Aged, 80 and over, Female, Glossitis immunology, Herpes Simplex diagnosis, Herpes Simplex immunology, Humans, Immunocompromised Host, Remission, Spontaneous, Glossitis pathology, Glossitis virology, Herpes Simplex pathology, Herpesvirus 1, Human isolation & purification
- Published
- 2020
- Full Text
- View/download PDF
24. S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells.
- Author
-
Cayrefourcq L, De Roeck A, Garcia C, Stoebner PE, Fichel F, Garima F, Perriard F, Daures JP, Meunier L, and Alix-Panabières C
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Female, Humans, Male, Melanoma pathology, Middle Aged, Molecular Diagnostic Techniques methods, S100 Proteins genetics, S100 Proteins metabolism, Melanoma blood, Neoplastic Cells, Circulating metabolism, Software
- Abstract
Metastatic melanoma is one of the most aggressive and drug-resistant cancers with very poor overall survival. Circulating melanoma cells (CMCs) were first described in 1991. However, there is no general consensus on the clinical utility of CMC detection, largely due to conflicting results linked to the use of heterogeneous patient populations and different detection methods. Here, we developed a new EPithelial ImmunoSPOT (EPISPOT) assay to detect viable CMCs based on their secretion of the S100 protein (S100-EPISPOT). Then, we compared the results obtained with the S100-EPISPOT assay and the CellSearch
® CMC kit using blood samples from a homogeneous population of patients with metastatic melanoma. We found that S100-EPISPOT sensitivity was significantly higher than that of CellSearch® . Specifically, the percentage of patients with ≥2 CMCs was significantly higher using S100-EPISPOT than CellSearch® (48% and 21%, respectively; p = 0.0114). Concerning CMC prognostic value, only the CellSearch® results showed a significant association with overall survival ( p = 0.006). However, due to the higher sensitivity of the new S100-EPISPOT assay, it would be interesting to determine whether this functional test could be used in patients with non-metastatic melanoma for the early detection of tumor relapse and for monitoring the treatment response.- Published
- 2019
- Full Text
- View/download PDF
25. Proteasome 19S RP and translation preinitiation complexes are secreted within exosomes upon serum starvation.
- Author
-
Bec N, Bonhoure A, Henry L, Berry L, Larroque C, Coux O, Stoebner PE, and Vidal M
- Subjects
- Autophagy, Autophagy-Related Protein 5 genetics, Autophagy-Related Protein 5 metabolism, Cell Line, Tumor, Culture Media, Serum-Free pharmacology, Cytoplasmic Granules metabolism, Eukaryotic Initiation Factors metabolism, Exosomes drug effects, Humans, Protein Transport, Ribosomal Proteins metabolism, Vesicular Transport Proteins metabolism, Exosomes metabolism, Proteasome Endopeptidase Complex metabolism, Proteome metabolism
- Abstract
The aim of our study was to investigate the impact of macroautophagy on exosome secretion. Exosomes are small membrane vesicles released in the extracellular space upon fusion of multivesicular endosomes with the plasma membrane. They were initially discovered as a way to remodel the reticulocyte plasma membrane before entering the blood circulation (Current Opinion in Hematology 2010, 17:177-183) and are now essentially studied as mediators of intercellular communication. Using iTRAQ proteomics, we compared the protein composition of purified exosomes secreted by cells impaired or not for macroautophagy by Atg5 depletion, during serum starvation conditions or complete medium culture. We show that the absence of serum modifies exosomal content, especially inducing secretion of two cytoplasmic protein complexes, namely proteasomal 19S regulatory particle (RP) and components of noncanonical translation preinitiation complex (PIC). This process is enhanced when autophagy is impaired by Atg5 depletion. Moreover, we show that the proteasome 20S core particle (CP) is released in the extracellular space. However, in striking contrast to what seen for its 19S RP regulator, release is independent of the exosomal vesicles, Atg5 expression and cell culture conditions. Exosome secretion can thus be considered as a cell process that participates in and reflects cell homeostasis, and care must be taken when studying potential extracellular function of exosomes due to the possible copurification of proteasome 20S CP., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
26. Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
- Author
-
Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, and Lebbé C
- Subjects
- Aged, Cohort Studies, Disease Progression, Female, France, Humans, Male, Melanoma pathology, Melanoma therapy, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Prognosis, Progression-Free Survival, Prospective Studies, Skin Neoplasms pathology, Skin Neoplasms therapy, Survival Rate, Time Factors, Melanoma diagnosis, Skin Neoplasms diagnosis
- Abstract
Importance: The prognosis of advanced melanoma has been greatly improved by new therapeutic agents and clinicians rely on dynamic signals to drive their therapeutic choices. Although the kinetics of metastatic disease seem to be correlated with survival, progression of the localized disease is not predictable., Objective: To assess whether progression of metastatic disease is associated with the time to the first distant recurrence of melanoma., Design, Setting, and Participants: This study was conducted from March 1, 2013, to September 1, 2017, among 638 adults with unresectable stage III or IV melanoma within the French multicentric prospective cohort MelBase. Patients treated with first-line immunotherapies, targeted therapies, or chemotherapy were included. Patients with unknown primary or de novo metastatic melanoma were not included. Data were analyzed from March 1, 2013, to December 1, 2017., Main Outcomes and Measures: The date of primary excision and time to first distant recurrence, progression-free survival, and overall survival were collected. Cox proportional hazards regression models were planned to assess the association between time to first distant recurrence and progression-free survival or overall survival, which was evaluated in terms of hazard ratio (HR). Time to recurrence was analyzed both as a continuous and categorical variable (<12 months, 12-24 months, and >24 months)., Results: A total of 638 patients (272 women and 366 men; median age, 64 years [interquartile range, 52-73 years]) were included in the study. The median time from primary excision to first distant recurrence was 25 months (interquartile range, 12-55 months). There was no evidence of association of the time to recurrence with progression-free survival, both when analyzed as a continuous variable (HR, 0.99; 95% CI, 0.99-1.01) or after categorization (12-24 months: HR, 0.75; 95% CI, 0.56-1.02; >24 months: HR, 0.62; 95% CI; 0.47-1.01). There was no evidence of association of the time to recurrence with overall survival, both when analyzed as a continuous variable (HR, 0.99; 95% CI, 0.98-1.02) or after categorization (12-24 months: HR, 0.76; 95% CI, 0.54-1.07; >24 months: HR, 0.61; 95% CI, 0.54-1.03). Those results remained nonsignificant after stratification by treatment., Conclusions and Relevance: In the MelBase cohort, time to recurrence of metastatic melanoma appears not to be associated with progression-free survival or overall survival.
- Published
- 2019
- Full Text
- View/download PDF
27. A case of fluoroscopy-induced squamous cell carcinoma following repeated percutaneous coronary interventions.
- Author
-
Samaran Q, Croci-Torti A, Dandurand M, Marque M, Meunier L, and Stoebner PE
- Subjects
- Aged, Axilla, Humans, Male, Percutaneous Coronary Intervention, Radiodermatitis etiology, Carcinoma, Squamous Cell etiology, Fluoroscopy adverse effects, Neoplasms, Radiation-Induced etiology, Skin Neoplasms etiology
- Published
- 2019
- Full Text
- View/download PDF
28. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
- Author
-
Tétu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dreno B, Mohamed S, Ballon A, Porcher R, and Lebbe C
- Subjects
- Aged, Brain Neoplasms immunology, Brain Neoplasms secondary, Combined Modality Therapy methods, Female, Humans, Immunotherapy methods, Male, Melanoma immunology, Melanoma pathology, Middle Aged, Proportional Hazards Models, Prospective Studies, Brain Neoplasms radiotherapy, Brain Neoplasms therapy, Melanoma drug therapy, Melanoma radiotherapy
- Abstract
Background: Melanoma brain metastases (MBMs) are historically associated with poor prognosis. Radiation therapy is conventionally associated with a high local control rate. Development of targeted therapy and immunotherapy has improved overall survival (OS) and intracranial response rate, but about 50% of patients failed to respond to these novel therapies. The objective of this study was to assess the impact of combined radiotherapy (cRT) on overall survival in a large multicenter real-life prospective cohort of patients with MBM treated with immunotherapy or targeted therapy., Patients and Methods: Clinical data from 262 patients with MBM were collected via MelBase, a French multicentric biobank prospectively enrolling unresectable stage III or IV melanoma. Two groups were defined: patients receiving cRT (cRT group) or not receiving cRT (no-cRT group). Primary end-point was OS. Propensity score weighting was used to correct for indication bias., Results: Among the 262 patients, 93 (35%) received cRT (cRT group). The patients were treated with immunotherapy in 69% and 60% and with targeted therapy in 31% and 40% of the cRT and no-cRT groups, respectively. With a median follow-up of 6.9 months, median OS was 16.8 months and 6.9 months in the cRT and no-cRT groups, respectively. After propensity score weighting, cRT was associated with longer OS (hazard ratio = 0.6, 95% confidence interval: 0.4-0.8; p=0.007). Median OS after ponderation was 15.3 months and 6.2 months in the cRT and no-cRT groups, respectively., Conclusion: This study shows that cRT may be associated with a significant decrease of 40% in the risk of death in patients with MBM treated with systemic therapy., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
29. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
- Author
-
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, and Borget I
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents economics, Cohort Studies, Cost-Benefit Analysis, Drug Costs, Female, France, Health Care Costs, Hospital Costs, Humans, Immunotherapy economics, Immunotherapy statistics & numerical data, Kaplan-Meier Estimate, Male, Melanoma economics, Melanoma mortality, Middle Aged, Molecular Targeted Therapy economics, Molecular Targeted Therapy statistics & numerical data, Prospective Studies, Survival Rate, Therapies, Investigational statistics & numerical data, Young Adult, Antineoplastic Agents therapeutic use, Melanoma drug therapy, Therapies, Investigational economics
- Abstract
Purpose: Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at €1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice., Methods: Clinical and economic data (treatments, hospitalisations, radiotherapy sessions, visits, imaging and biological exams) were extracted from the prospective MelBase cohort, collecting individual data in 955 patients in 26 hospitals, from diagnosis of metastatic disease until death. Survival was estimated by the Kaplan-Meier method. Costs were calculated from the health insurance perspective using French tariffs. For live patients, survival and costs were extrapolated using a multistate model, describing the 5-year course of the disease according to patient prognostic factors and number of treatment lines., Results: Since the availability of new drugs, the mean survival time of MM patients has increased to 23.6 months (
95% confidence interval [CI] :21.2;26.6), with 58% of patients receiving a second line of treatment. Mean management costs increased to €269,682 (95% CI:244,196;304,916) per patient. Drugs accounted for 80% of the total cost., Conclusion: This study is the first that evaluated the impact of immunotherapies and targeted therapies both on survival and cost in real-life conditions. Alongside the introduction of breakthrough therapies in the first and subsequent lines, MM has been associated with a significant increase in survival but also in costs, raising the question of financial sustainability., (Copyright © 2018 Elsevier Ltd. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
30. [What's new in dermatological research?]
- Author
-
Stoebner PE
- Subjects
- Animals, Disease Models, Animal, Humans, Mice, Skin Diseases diagnosis, Skin Diseases etiology, Skin Diseases genetics, Skin Diseases therapy, Translational Research, Biomedical trends, Dermatology trends, Research trends
- Abstract
This manuscript provides a selection of dermatological research manuscripts published from September 2016 to August 2017. It is not an exhaustive review but rather a selection of manuscripts susceptible to modify the dermatological practice or affording new pathophysiologic mechanisms and new therapeutic approaches. The following areas of interest are concerned: recognition of dermatological images by artificial intelligence, new concepts in atopic dermatitis, wound repair and hair growth cycle. New data concerning melanomagenesis, epidermolysis bullosa simplex and drug eruption are also highlighted., (© 2017 Elsevier Masson SAS. Tous droits réservés.)
- Published
- 2017
- Full Text
- View/download PDF
31. The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin.
- Author
-
Zieba BA, Henry L, Lacroix M, Jemaà M, Lavabre-Bertrand T, Meunier L, Coux O, and Stoebner PE
- Subjects
- Apoptosis, Biopsy, Blotting, Western, Cell Differentiation, Cell Line, Cell Proliferation, Cytoplasm, Epidermal Cells, Epidermis pathology, Humans, Keratinocytes metabolism, Molecular Chaperones genetics, Native Polyacrylamide Gel Electrophoresis, RNA Interference, RNA, Small Interfering metabolism, Keratinocytes pathology, Molecular Chaperones metabolism, Proteasome Endopeptidase Complex metabolism, Psoriasis pathology, RNA, Messenger metabolism
- Abstract
Background: The ubiquitin proteasome pathway is involved in the pathogenesis of psoriasis and proteasome subunits are increased in lesional psoriatic skin. Recent works have highlighted that proteasome levels can be regulated through modulation of proteasome assembly notably by the proteasome maturation protein POMP., Objectives: To investigate whether proteasome assembly and POMP expression are modified in psoriatic skin., Methods: Proteasome assembly as well as expression of proteasome regulators were assessed in non-lesional and lesional psoriatic skin using native gel electrophoresis and western blots respectively. The protein and mRNA expression levels of POMP were compared by western blots, immunohistochemistry and quantitative polymerase chain reaction. The role of POMP in keratinocyte proliferation and differentiation was assessed by silencing POMP gene expression by RNA interference in human immortalized keratinocyte HaCaT cells., Results: Both 20S and 26S proteasomes (and their respective proteolytic activities) as well as the main proteasome regulators are increased in lesional psoriatic skin. POMP binds to 20S precursor complexes and is overexpressed in lesional epidermal psoriatic skin, supporting that POMP-mediated proteasome assembly is increased in psoriatic skin. POMP silencing inhibited HaCaT cell proliferation and induced apoptosis through the inhibition of the proteasome assembly. Moreover POMP partial depletion decreased the expression of the differentiation markers keratin 10 and involucrin during the [Ca
2+ ]-induced HaCaT cells differentiation., Conclusion: Altogether these results establish a potential role for POMP and proteasome assembly in psoriasis pathogenesis., (Copyright © 2017 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
32. Clinical and immunological features and outcome of anti-p200 pemphigoid.
- Author
-
Commin MH, Schmidt E, Duvert-Lehembre S, Lasek A, Morice C, Estival JL, Debarbieux S, Rigal E, Pauwels C, De Quatrebarbes J, Roussel A, Goujon E, Stoebner PE, Jouen F, and Joly P
- Subjects
- Aged, Aged, 80 and over, Dermatologic Agents therapeutic use, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Pemphigoid, Bullous drug therapy, Pemphigoid, Bullous immunology, Prognosis, Recurrence, Retrospective Studies, Laminin immunology, Pemphigoid, Bullous pathology
- Abstract
Background: Anti-p200 pemphigoid is a rare autoimmune blistering disease (AIBD) of the dermoepidermal junction, characterized by autoantibodies to laminin γ1. The clinical course of anti-p200 pemphigoid in patients remains poorly investigated., Objectives: We aimed to describe the clinical and immunological features and the course of a series of patients with anti-p200 pemphigoid., Methods: We conducted a retrospective study by immunoblotting detection of sera on 200-kDa dermal protein extracts from the register of the French reference centre for AIBD. We recorded the clinical and immunological features and the course of patients., Results: A total of 14 patients with a mean age 81·6 ± 6·5 years were included. Only one patient had an associated neurological condition and one had psoriasis. Twelve patients had atypical clinical presentation, including eczematous, urticarial, prurigo-like, dyshydrosis-like and rosette-like skin lesions. Eight patients (57%) had mucosal involvement. Immunoblot analysis of sera on dermal and epidermal extracts showed a 200-kDa band in 14 and 10 cases, respectively. All eight of the sera tested by enzyme-linked immunosorbent assay detected recombinant human laminin γ1. Disease control was obtained in six of nine patients treated with topical corticosteroids, and four of five patients who received systemic treatment. Seven patients relapsed (50%) and five patients (36%) died during the median follow-up time of 12·6 months. At the end of the study, only one of the nine living patients was in complete remission off therapy., Conclusions: Many patients with anti-p200 pemphigoid had heterogeneous clinical presentation and a more severe prognosis than previously suspected., (© 2016 British Association of Dermatologists.)
- Published
- 2016
- Full Text
- View/download PDF
33. Documented cutaneous loxoscelism in the south of France: an unrecognized condition causing delay in diagnosis.
- Author
-
Rubenstein E, Stoebner PE, Herlin C, Lechiche C, Rollard C, Laureillard D, and Sotto A
- Subjects
- Adult, Animals, Asthenia, Delayed Diagnosis, Female, France, Humans, Phosphoric Diester Hydrolases, Spider Venoms, Spiders, Leg Ulcer, Necrosis, Spider Bites, Thigh pathology
- Abstract
Background: Loxoscelism is an envenomation due to a bite by spiders of the genus Loxosceles, very well known on the American continent but unrecognized in Europe., Case Report: We report the case of a 36-year-old woman, without any medical history or treatment, who went to a University Hospital in the South of France, for a painful skin lesion on the internal part of her left thigh, which appeared in the morning and developed rapidly during the day. She was directed to the infectious disease department with a diagnosis of skin infection. In spite of the antibiotics, the lesion increased, with a hemorrhagic central blister, an irregular ecchymotic center, a pale perimeter, and an extensive inflammatory and indurate oedema affecting the whole thigh. There was also a low-grade fever, chills, intense pain and a generalized scarlatiniform exanthema. The lesion was finally diagnosed as cutaneous loxoscelism, then confirmed by collection and identification of a Loxosceles rufescens spider killed by the patient the morning of the occurrence of the lesion. Following an initial symptomatic treatment, the development of a necrotic ulcer justified a delayed surgical reconstruction, after stabilization of the lesion., Conclusions: Loxosceles bites are usually painless and rarely noticed by patients, often leading to a presumptive diagnosis. Therefore, in the case of a dermonecrotic lesion developing unfavourably with antibiotics, cutaneous loxoscelism should be one of the diagnoses to be considered.
- Published
- 2016
- Full Text
- View/download PDF
34. AMPK/HuR-Driven IL-20 Post-Transcriptional Regulation in Psoriatic Skin.
- Author
-
Garcin G, Guiraud I, Lacroix M, Genthon C, Rialle S, Joujoux JM, Meunier L, Lavabre-Bertrand T, Stoebner PE, and Le Gallic L
- Subjects
- AMP-Activated Protein Kinases genetics, Animals, Biopsy, Needle, Cells, Cultured, Disease Models, Animal, ELAV-Like Protein 1 genetics, Humans, Immunohistochemistry, Keratinocytes cytology, Keratinocytes metabolism, Mice, Mice, Inbred C57BL, RNA Interference, RNA, Messenger genetics, Random Allocation, Real-Time Polymerase Chain Reaction methods, Skin cytology, Skin pathology, Statistics, Nonparametric, Up-Regulation, AMP-Activated Protein Kinases metabolism, ELAV-Like Protein 1 metabolism, Gene Expression Regulation, Interleukins genetics, Psoriasis genetics, Psoriasis pathology
- Abstract
IL-20 is involved in the development of skin psoriasis. The molecular mechanisms underlying IL-20 overexpression in psoriatic epidermis remain to be elucidated. We showed that IL-20 was primarily upregulated in psoriatic skin at the post-transcriptional level. The RNA-binding protein HuR relocalized to the cytoplasm of keratinocytes (KCs) of psoriatic patients, suggesting that it stabilizes numerous transcripts, as observed in the human KC cell lines used to assess IL-20 mRNA. We characterized epidermal HuR RNA targets in psoriatic skin using ribonucleoprotein immunoprecipitation analyzed via high-throughput sequencing. Numerous transcripts that are upregulated in psoriasis were targeted by HuR, supporting the participation of HuR in pathogenic processes such as morphological changes, innate and adaptive immune responses, and metabolic inflammatory responses. Finally, we identified the metabolic sensor AMP-activated protein kinase (AMPK) as being responsible for HuR cytoplasmic relocalization because its activity was severely impaired in human psoriatic epidermis, and in vivo drug-mediated AMPK inhibition in mouse epidermis promoted HuR cytoplasmic localization, IL-20 overproduction, acanthosis, and hyperkeratosis. These results provide insights into the molecular links between metabolism and post-transcriptional networks during chronic inflammation.
- Published
- 2015
- Full Text
- View/download PDF
35. Defining and recognising locally advanced basal cell carcinoma.
- Author
-
Amici JM, Battistella M, Beylot-Barry M, Chatellier A, Dalac-Ra S, Dreno B, Falandry C, Froget N, Giacchero D, Grob JJ, Guerreschir P, Leccia MT, Malard O, Mortier L, Routier E, Stefan A, Stefan D, Stoebner PE, and Basset-Seguin N
- Subjects
- Congresses as Topic, Europe epidemiology, Humans, Morbidity trends, Carcinoma, Basal Cell epidemiology, Carcinoma, Basal Cell pathology, Carcinoma, Basal Cell therapy, Dermatology, Practice Guidelines as Topic, Skin Neoplasms epidemiology, Skin Neoplasms pathology, Skin Neoplasms therapy, Societies, Medical
- Abstract
Background: Rarely, basal cell carcinomas (BCCs) have the potential to become extensively invasive and destructive, a phenomenon that has led to the term "locally advanced BCC" (laBCC). We identified and described the diverse settings that could be considered "locally advanced"., Methods: The panel of experts included oncodermatologists, dermatological and maxillofacial surgeons, pathologists, radiotherapists and geriatricians. During a 1-day workshop session, an interactive flow/sequence of questions and inputs was debated., Results: Discussion of nine cases permitted us to approach consensus concerning what constitutes laBCC. The expert panel retained three major components for the complete assessment of laBCC cases: factors of complexity related to the tumour itself, factors related to the operability and the technical procedure, and factors related to the patient. Competing risks of death should be precisely identified. To ensure homogeneous multidisciplinary team (MDT) decisions in different clinical settings, the panel aimed to develop a practical tool based on the three components., Conclusion: The grid presented is not a definitive tool, but rather, it is a method for analysing the complexity of laBCC.
- Published
- 2015
- Full Text
- View/download PDF
36. Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma.
- Author
-
Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Dompmartin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, and Mateus C
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Merkel Cell immunology, Carcinoma, Merkel Cell mortality, Carcinoma, Merkel Cell pathology, Chi-Square Distribution, Disease-Free Survival, Feasibility Studies, Female, France, Humans, Kaplan-Meier Estimate, Logistic Models, Lymphatic Metastasis, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Predictive Value of Tests, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Risk Factors, Sentinel Lymph Node Biopsy, Sex Factors, Skin Neoplasms immunology, Skin Neoplasms mortality, Skin Neoplasms pathology, Time Factors, Treatment Outcome, Young Adult, Carcinoma, Merkel Cell therapy, Immunocompromised Host, Lymph Nodes pathology, Neoplasm Recurrence, Local, Skin Neoplasms therapy
- Abstract
The prognostic value of the sentinel lymph node in Merkel cell carcinoma (MCC) has been examined previously in heterogeneous retrospective studies. The current retrospective study included a homogeneous population of patients with a localized MCC, all staged with sentinel lymph node biopsy. Factors associated with 3-year progression-free survival were analysed using logistic regression. The sentinel lymph node was positive in 32% of patients. The recurrence rate was 26.9%. In first analyses (n = 108), gender (p = 0.0115) and the presence of immunosuppression (p = 0.0494) were the only significant independent factors. In further analyses (n = 80), excluding patients treated with regional radiotherapy, sentinel lymph node status was the only significant prognostic factor (p = 0.0281). Immunosuppression and positive sentinel lymph node are associated with a worse prognosis in patients with MCC. Nodal irradiation impacts on the prognostic value of the sentinel lymph node status.
- Published
- 2015
- Full Text
- View/download PDF
37. [Massive localized lymphedema].
- Author
-
Best M, Garcia C, Gonzalez S, Dandurand M, Marque M, Stoebner PE, and Meunier L
- Subjects
- Adult, Female, Humans, Lymphedema surgery, Lymphedema etiology, Obesity, Morbid complications
- Abstract
Background: Massive localized lymphedema (MLL) is a benign soft-tissue lesion that usually presents as a large and isolated mass in morbidly obese adults., Patients and Methods: We report the case of a 39-year-old woman presenting obesity and multiple MLL. There was a large tumor in the left groin and two smaller lesions on the backs of the thighs., Discussion: MLL is a benign tumor that must be removed wherever possible because such tumors may degenerate into angiosarcomas in 13% of cases. MLL is probably secondary to a prolonged obstruction of lymphatic vessels due to marked excess of adipose tissue., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
38. [Metastatic cervical fasciitis revealing invasive lobular breast carcinoma].
- Author
-
Munoz J, Garcia C, Joujoux JM, Dandurand M, Meunier L, and Stoebner PE
- Subjects
- Aged, Carcinoma, Lobular pathology, Female, Head and Neck Neoplasms pathology, Humans, Neoplasm Invasiveness, Breast Neoplasms pathology, Carcinoma, Lobular complications, Carcinoma, Lobular secondary, Fasciitis etiology, Head and Neck Neoplasms complications, Head and Neck Neoplasms secondary
- Abstract
Background: We describe the case of a 71-year-old woman presenting cervical metastatic fasciitis with invasive lobular carcinoma (ILC) of the breast., Patients and Methods: The patient consulted for a deep and painless skin infiltration of the neck associated with dysphagia and restricted cervical mobility. Skin and muscle biopsies were normal. Muscle fascia biopsy showed a linear infiltration of metastatic cells in "single file", revealing ILC of the right breast., Discussion: ILCs have a particular metastatic pattern. They can permeate through tissue planes, infiltrate solid organs and spread on serous membranes in an insidious fashion., Conclusion: Our case shows that ILC can metastasise into muscular fascia, causing "fasciitis-like" symptoms. Dermatologists should be aware of this particular pattern of dissemination., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
39. Benefit of gluten-free diet in acrodermatitis continua of Hallopeau associated with celiac disease: a case report.
- Author
-
Fabre C, Lefèvre M, Dandurand M, Meunier L, and Stoebner PE
- Subjects
- Acrodermatitis complications, Acrodermatitis pathology, Aged, Celiac Disease complications, Humans, Male, Psoriasis complications, Psoriasis pathology, Acrodermatitis diet therapy, Celiac Disease diet therapy, Diet, Gluten-Free, Psoriasis diet therapy
- Published
- 2014
- Full Text
- View/download PDF
40. Human papillomavirus type 16-induced skin squamous cell carcinoma located on the groin of immunocompetent patients.
- Author
-
Croci-Torti A, Tamalet C, Segondy M, Dandurand M, Meunier L, and Stoebner PE
- Subjects
- Female, Groin, Humans, Immunocompetence, Middle Aged, Carcinoma, Squamous Cell virology, Human papillomavirus 16, Papillomavirus Infections, Skin Neoplasms virology
- Published
- 2014
- Full Text
- View/download PDF
41. [Acquired reactive perforating collagenosis].
- Author
-
Bekkali N, Gil Bistes D, Joujoux JM, Meunier L, and Stoebner PE
- Subjects
- Aged, Biopsy, Collagen chemistry, Collagen Diseases etiology, Diagnosis, Differential, Glycation End Products, Advanced, Humans, Male, Pruritus etiology, Skin Diseases, Genetic diagnosis, Staining and Labeling, Collagen Diseases diagnosis, Diabetes Mellitus, Type 2 complications
- Published
- 2014
- Full Text
- View/download PDF
42. Macular lymphocytic arteritis: three cases questioning its classification as primary lymphocytic vasculitis.
- Author
-
Garcia C, Dandurand M, Roger P, Joujoux JM, Meunier L, and Stoebner PE
- Subjects
- Adult, Arteritis classification, Arteritis immunology, Diagnosis, Differential, Female, Humans, Hyperpigmentation immunology, Leg pathology, Middle Aged, Severity of Illness Index, Skin Diseases, Vascular pathology, Arteritis pathology, Hyperpigmentation pathology, Lymphocytes immunology
- Abstract
Background: Macular arteritis, macular lymphocytic arteritis (MLA) or lymphocytic thrombophilic arteritis all correspond to an identical new clinicopathological entity. Its individualization as a primary cutaneous lymphocytic arteritis is still controversial for certain authors as it could represent a latent form of cutaneous polyarteritis nodosa., Materials and Methods: We report here 3 additional cases of MLA, present a review of the literature and discuss the disease's nosology., Results: MLA is characterized clinically by a benign skin eruption consisting in bilateral asymptomatic erythematous/hyperpigmented macules mainly located on the lower legs and histologically by a medium-sized cutaneous lymphocytic prominent arteritis present in early cutaneous lesions., Conclusion: These findings support that MLA may be considered as a chronic and indolent primary lymphocytic cutaneous arteritis. Nevertheless, in some cases the objective obliteration of cutaneous vessels underlines the need for continuous monitoring in MLA patients., (© 2013 S. Karger AG, Basel.)
- Published
- 2014
- Full Text
- View/download PDF
43. [Micrographic surgery: indications and practical applications in the dermatologist's office].
- Author
-
Ly A, Habib F, Zimmermann U, Gentil-Perret A, Joujoux JM, Clerici T, Stoebner PE, Chaussade V, and Sei JF
- Subjects
- Frozen Sections, Humans, Mohs Surgery methods, Neoplasm Invasiveness, Neoplasm, Residual, Paraffin Embedding, Skin Neoplasms pathology, Ambulatory Surgical Procedures methods, Dermatologic Surgical Procedures methods, Microsurgery methods, Physicians' Offices, Skin Neoplasms surgery
- Published
- 2013
- Full Text
- View/download PDF
44. Florid pseudoepitheliomatous hyperplasia related to tattoo: a case report.
- Author
-
de Roeck A, Joujoux JM, Fournier F, Dandurand M, Meunier L, and Stoebner PE
- Subjects
- Biopsy, Diagnosis, Differential, Female, Humans, Hyperplasia etiology, Hyperplasia pathology, Hyperplasia surgery, Middle Aged, Skin Diseases pathology, Skin Diseases surgery, Skin Diseases etiology, Tattooing adverse effects
- Abstract
Pseudoepitheliomatous hyperplasia is a benign condition defined by an exuberant proliferation of the epithelium with downward progression into the dermis. It may occur in reaction to several conditions including chronic cutaneous wound. We describe an unusual case of a florid pseudoepitheliomatous hyperplasia mimicking a well-differentiated squamous cell carcinoma, restricted to the red part of a rose tattoo., (© 2012 The Authors. International Wound Journal © 2012 John Wiley & Sons Ltd and Medicalhelplines.com Inc.)
- Published
- 2013
- Full Text
- View/download PDF
45. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
- Author
-
Henry L, Fabre C, Guiraud I, Bastide S, Fabbro-Peray P, Martinez J, Lavabre-Bertrand T, Meunier L, and Stoebner PE
- Subjects
- Adult, Aged, Aged, 80 and over, Colorimetry, Enzyme-Linked Immunosorbent Assay, Female, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Male, Melanoma blood, Melanoma secondary, Middle Aged, Neoplasm Staging, Plasma, Predictive Value of Tests, Prognosis, Proportional Hazards Models, S100 Calcium Binding Protein beta Subunit, Skin Neoplasms blood, Skin Neoplasms pathology, Biomarkers, Tumor blood, Extracellular Matrix Proteins blood, L-Lactate Dehydrogenase blood, Melanoma diagnosis, Neoplasm Proteins blood, Nerve Growth Factors blood, Proteasome Endopeptidase Complex blood, S100 Proteins blood, Skin Neoplasms diagnosis
- Abstract
Plasmatic proteasome (p-proteasome) has recently been described as a new marker for metastatic melanoma. The objective of this study was to compare the diagnostic and prognostic values of p-proteasome with three other melanoma serological markers: S100B protein, melanoma inhibitory activity protein (MIA) and lactate dehydrogenase (LDH) in the plasma of 121 stage I-IV melanoma patients. Laboratory analyses were performed by standardized ELISA (p-proteasome, MIA), immunoluminometric assay (S100B) and colorimetry (LDH). We found that all markers were relevant for discriminating metastatic from nonmetastatic patients but p-proteasome displayed the highest diagnostic accuracy. P-proteasome and S100B were the most sensitive (58.1%) and p-proteasome and MIA the most specific (98.7 and 100%) in detecting metastatic disease. P-proteasome and S100B had the highest area under receiver operating characteristics curve, 0.811 (95% CI: 0.725-0.897) and 0.822 (95% CI: 0.738-0.906), respectively. These two markers were the best in detecting patients with lymph node metastases. S100B, MIA and LDH diagnostic accuracy was increased when these markers were combined with p-proteasome. As shown with univariate analysis, shorter progression-free and overall survival rates were significantly associated with elevated plasma levels of each markers. The multivariate Cox regression analysis identified p-proteasome as the only independent predictor of a poorer progression-free survival (p = 0.030). In conclusion, this comparative study established that p-proteasome quantification in combination with other melanoma biomarkers is an attractive approach for the biological follow-up of melanoma patients., (Copyright © 2012 UICC.)
- Published
- 2013
- Full Text
- View/download PDF
46. MC1R expression in HaCaT keratinocytes inhibits UVA-induced ROS production via NADPH oxidase- and cAMP-dependent mechanisms.
- Author
-
Henri P, Beaumel S, Guezennec A, Poumès C, Stoebner PE, Stasia MJ, Guesnet J, Martinez J, and Meunier L
- Subjects
- Adaptor Proteins, Signal Transducing, Adaptor Proteins, Vesicular Transport metabolism, Cell Line, Cyclic AMP-Dependent Protein Kinases antagonists & inhibitors, Cyclic AMP-Dependent Protein Kinases metabolism, Dose-Response Relationship, Radiation, ErbB Receptors antagonists & inhibitors, ErbB Receptors metabolism, Extracellular Signal-Regulated MAP Kinases antagonists & inhibitors, Extracellular Signal-Regulated MAP Kinases metabolism, Humans, Keratinocytes drug effects, Keratinocytes enzymology, Oxidative Stress drug effects, Phosphorylation, Protein Kinase Inhibitors pharmacology, Receptor, Melanocortin, Type 1 genetics, Signal Transduction radiation effects, Time Factors, Transfection, alpha-MSH metabolism, Cyclic AMP metabolism, Keratinocytes radiation effects, NADPH Oxidases metabolism, Oxidative Stress radiation effects, Reactive Oxygen Species metabolism, Receptor, Melanocortin, Type 1 metabolism, Ultraviolet Rays
- Abstract
Ultraviolet A (UVA) radiations are responsible for deleterious effects, mainly due to reactive oxygen species (ROS) production. Alpha-melanocyte stimulating hormone (α-MSH) binds to melanocortin-1 receptor (MC1R) in melanocytes to stimulate pigmentation and modulate cutaneous inflammatory responses. MC1R may be induced in keratinocytes after UV exposure. To investigate the effect of MC1R signaling on UVA-induced ROS (UVA-ROS) production, we generated HaCaT cells that stably express human MC1R (HaCaT-MC1R) or the Arg151Cys (R(151)C) non-functional variant (HaCaT-R(151)C). We then assessed ROS production immediately after UVA exposure and found that: (1) UVA-ROS production was strongly reduced in HaCaT-MC1R but not in HaCaT-R(151)C cells compared to parental HaCaT cells; (2) this inhibitory effect was further amplified by incubation of HaCaT-MC1R cells with α-MSH before UVA exposure; (3) protein kinase A (PKA)-dependent NoxA1 phosphorylation was increased in HaCaT-MC1R compared to HaCaT and HaCaT-R(151)C cells. Inhibition of PKA in HaCaT-MC1R cells resulted in a marked increase of ROS production after UVA irradiation; (4) the ability of HaCaT-MC1R cells to produce UVA-ROS was restored by inhibiting epidermal growth factor receptor (EGFR) or extracellular signal-regulated kinases (ERK) activity before UVA exposure. Our findings suggest that constitutive activity of MC1R in keratinocytes may reduce UVA-induced oxidative stress via EGFR and cAMP-dependent mechanisms., (Copyright © 2011 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
47. Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin.
- Author
-
Henry L, Le Gallic L, Garcin G, Coux O, Jumez N, Roger P, Lavabre-Bertrand T, Martinez J, Meunier L, and Stoebner PE
- Subjects
- Adult, Aged, Aged, 80 and over, Arthritis, Psoriatic enzymology, Cells, Cultured, Female, Humans, Immunohistochemistry, Interferon-gamma pharmacology, Male, Middle Aged, RNA, Messenger metabolism, Young Adult, Proteasome Endopeptidase Complex metabolism, Psoriasis enzymology
- Abstract
Background: Deregulation of the proteasome pathway has been shown to be involved in the pathogenesis of several inflammatory disorders. To date limited information exists on proteasome and immunoproteasome expression and activity in psoriasis skin., Objectives: To investigate the potential role of proteasomes in the pathogenesis of psoriasis., Methods: Thirty-six patients with psoriasis and 40 healthy subjects were included. The protein and mRNA expression levels and proteolytic activity of proteasome and immunoproteasome subunits were determined using immunohistochemistry, quantitative polymerase chain reaction and fluorogenic peptide substrate in lesional and nonlesional psoriasis skin. We additionally measured the plasmatic proteasome (p-proteasome) levels using enzyme-linked immunosorbent assay., Results: We reveal an increased expression of proteasome and immunoproteasome subunits but stable mRNA levels in lesional psoriasis skin as compared with nonlesional psoriasis skin (n = 19), suggesting that proteasome and immunoproteasome expression is regulated post-transcriptionally. This proteasome overexpression was associated with a significant increase of the proteasomal chymotrypsin-like activity that was threefold higher in lesional skin than in nonlesional skin (n = 3). p-Proteasome levels were enhanced in patients with psoriasis (mean ± SEM 3960 ± 299 ng mL(-1) , range 1484-8987) when compared with controls (2535±187 ng mL(-1) , range 654-6446, P<0·001) and were significantly higher in psoriatic arthritis (4937±572 ng mL(-1) , range 2600-8987). In addition, they were correlated to the body surface area involved and appeared thus as a new biomarker of psoriasis severity., Conclusions: Altogether these results strongly suggest the involvement of the proteasome system in the pathogenesis of psoriasis and support the relevance of proteasome inhibitors in local or systemic treatment of psoriasis., (© 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.)
- Published
- 2011
- Full Text
- View/download PDF
48. Ross syndrome with sweating anomaly associated with Sjögren syndrome: An infrared thermo-graphic case study.
- Author
-
Luong M, Jomir L, Labauge P, Dandurand M, Meunier L, and Stoebner PE
- Subjects
- Adult, Female, Humans, Hyperhidrosis diagnosis, Reflex, Abnormal, Syndrome, Tonic Pupil, Autonomic Nervous System Diseases complications, Hyperhidrosis complications, Sjogren's Syndrome complications, Thermography
- Published
- 2011
- Full Text
- View/download PDF
49. Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma.
- Author
-
Henry L, Lavabre-Bertrand T, Douche T, Uttenweiler-Joseph S, Fabbro-Peray P, Monsarrat B, Martinez J, Meunier L, and Stoebner PE
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers blood, Disease-Free Survival, Female, Humans, L-Lactate Dehydrogenase blood, Male, Melanoma pathology, Middle Aged, Neoplasm Metastasis diagnosis, Neoplasm Staging, Predictive Value of Tests, Prognosis, Protein Subunits blood, ROC Curve, Recurrence, Survival Analysis, Young Adult, Melanoma blood, Melanoma diagnosis, Proteasome Endopeptidase Complex blood
- Abstract
Plasmatic proteasome (p-proteasome) also called circulating proteasome has recently been described as a tumor marker. We investigated the diagnostic and prognostic accuracies of p-proteasome levels in a melanoma population classified according to the American Joint Committee on Cancer staging system. Using an ELISA test, we measured p-proteasome levels in 90 patients and 40 controls between March 2003 and March 2008. The subunit composition of p-proteasomes was determined in metastatic melanoma by proteomic analysis. The mean p-proteasome levels were correlated with stages (P < 0.0001; r(S) = 0.664). They were significantly higher in patients with stage IV and stage III with lymph node metastasis (9187 ± 1294 and 5091 ± 454 ng/ml, respectively) compared to controls (2535 ± 187 ng/ml; P < 0.001), to stage I/II (2864 ± 166 ng/ml; P < 0.001) and to stage III after curative lymphadenectomy (2859 ± 271 ng/ml; P < 0.001). The diagnostic accuracy of p-proteasome was evaluated by receiver operating characteristic analysis. With a cut-off of 4300 ng/ml, diagnostic specificity and sensitivity of p-proteasome for regional or visceral metastases were respectively 96.3% and 72.2%. In univariate analysis, high p-proteasome levels (>4300 ng/ml) were significantly correlated with an increased risk of progression [hazard ratio (HR) = 7.34; 95% CI 3.54-15.21, P < 0.0001] and a risk of death (HR = 5.92; 95% CI 2.84-12.33, P < 0.0001). In multivariate analysis, high p-proteasome levels were correlated with a poorer clinical outcome in the subgroup analysis limited to patients with disease stages I, II and III. Proteomic analysis confirmed the presence of all proteasome and immunoproteasome subunits. Taken together, these results indicate that p-proteasomes are a new marker for metastatic dissemination in patients with melanoma., (© 2010 John Wiley & Sons A/S.)
- Published
- 2010
- Full Text
- View/download PDF
50. [Necrotic arachnidism in the south of France: two clinical cases of loxoscelism].
- Author
-
Pernet C, Dandurand M, Meunier L, and Stoebner PE
- Subjects
- Adult, Animals, Female, Follow-Up Studies, Humans, Spider Bites pathology, Spider Bites surgery, Surgical Flaps, Young Adult, Phosphoric Diester Hydrolases toxicity, Spider Bites diagnosis, Spider Venoms toxicity, Spiders classification
- Abstract
Background: loxosceles spiders are found throughout the world and are responsible for numerous cases of envenomation in America and Southern Europe. We describe, to our knowledge for the first time in France, two clinical cases of cutaneous loxoscelism., Case Report: two cases of skin necrosis arising after supposed spider bites were grouped together because of their similar clinical presentation: an initial painless bite and rapid development of an inflammatory and painful cutaneous lesion with a central hemorrhagic bulla surrounded by a perimeter of blanched skin (the "red, white, and blue" sign). The outcome in both cases was deep skin necrosis and chronic ulceration requiring surgical treatment., Discussion: loxoscelism can result in dermonecrosis. Although our cases were not documented by capture of the spider, the diagnosis of cutaneous loxoscelism was supported by the characteristic appearance of the lesion, a typical clinical course, elimination of differential diagnoses, and the confirmed presence of Loxosceles rufescens in the region., Conclusion: loxoscelism can occur in the south of France and although rare, must be considered in this region as a possible cause of skin necrosis., (2010 Elsevier Masson SAS. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.